Table 1.

Comparison of various identified functions, effects, and properties of MNRR1 and CHCHD10.

	MNRR1	CHCHD10
Protein length	151	142
CHCH domain	114–144	102–132
Interactions identified using mass spectrometry (BioGRID database)	97 total unique interactors (common interactors for both: C1QBP, NDUFS3, NDUFA8, COX5A, COX6A1, COX6C, ATP5H, ECH1, USMG5)	42 total unique interactors (common interactors for both: C1QBP, NDUFS3, NDUFA8, COX5A, COX6A1, COX6C, ATP5H, ECH1, USMG5)
Expression (Human Protein Atlas)	Expressed in all tissues at medium to high levels	Muscle, heart, liver (high), brain (medium), and low levels for other tissues
Mitochondrial function	Regulation of COX activity, ROS production [3], apoptosis [27]	Regulation of COX activity and ATP production [67], cristae morphology [68, 69]
Nuclear function	Transcriptional activator for COX4I2 and itself [3]	Not known to be localized to nucleus
Hypoxia sensitivity	Upregulated at 4% oxygen [25]	Unknown
Posttranslational regulation	Phosphorylated at Y99 by Abl2 kinase which activates mitochondrial function [20]	Unknown
Disease association (altered protein/transcript levels)	Huntington's disease [57], hepatocellular carcinoma [66], nonsmall cell lung carcinoma [28], lissencephaly [60]	Gastric cancer [91]
Mutation in protein associated with disease	Parkinson's disease [47]	Mitochondrial myopathy, amyotrophic lateral sclerosis, Alzheimer's disease, frontotemporal dementia, cerebellar ataxia, spinal muscular atrophy, Charcot-Marie-Tooth disease type 2A, motor neuron disease (specific references and mutations summarized in Table 2)
Functionally characterized mutations	Q112H [20], 300+5G>A [47]	S59L and P34S [68, 69], R15L/G58R [71]